Moderna has received initial feedback from the FDA on the design of the planned Phase 2 study, which is expected to begin in the second quarter of 2020.
The breakthrough therapy status will allow using of mobocertinib by patients with epidermal growth factor receptor (EGFR) exon 20 insertion mutations whose disease has advanced on or after
If approved for these indications, SIMPONI ARIA would be the first anti-tumor necrosis factor (TNF)-alpha biologic agent administered by intravenous infusion available for the treatment of these juvenile
The regulator has approved Sanofi’s biologics licence application (BLA) for MenQuadfi meningococcal (Groups A, C, Y, W) conjugate vaccine to prevent invasive meningococcal disease in persons aged two
Based on in silico models, AB001 acts on ACE-2 to inhibit the entry of the virus into the cell and also works on NSP15 to prevent its replication.
The randomised and global phase III study will evaluate the efficacy of Farxiga as a treatment in patients hospitalised with COVID-19 who are at risk of developing serious
The agreement specifies that George Mason University’s National Center for Biodefense and Infectious Diseases will provide their unique expertise and resources as a partner in the development of
Follicular lymphoma, which is said to be the second most common form of non-Hodgkins lymphoma (NHL), is an indolent lymphoma and represents around 22% of NHL cases. Claimed
“With the approval of our Emerphed Injection, Nexus Pharmaceuticals is looking to streamline the standard of care in the operating room,” said Mariam S. Darsot, Chief Executive Officer
Systemic sclerosis (SSc), also called as scleroderma, is a disfiguring, disabling and fatal rare autoimmune disease. Nintedanib is a tyrosine kinase inhibitor designed to target crucial receptors engaged
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.